FOLH1 and cancer: For the proof-of-concept study, we constructed a theranostic T-SMPDC system, which consists of a model vector, Lys-Urea-Glu, to target cancer-specific PSMA [49], which in tandem initiates cell internalization upon the vector binding [50,51].